Leukeran and Thalidomide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Leukeran (chlorambucil) and Thalidomide (thalidomide). Common drug interactions include failure to thrive among females and enterococcal infection among males.

The phase IV clinical study analyzes what interactions people have when they take Leukeran and Thalidomide. It is created by eHealthMe based on reports of 50 people who take the same drugs from the FDA, and is updated regularly.

What is Leukeran?

Leukeran has active ingredients of chlorambucil. eHealthMe is studying from 1,158 Leukeran users. Check the latest studies of Leukeran.

What is Thalidomide?

Thalidomide has active ingredients of thalidomide. eHealthMe is studying from 16,473 Thalidomide users. Check the latest studies of Thalidomide.

On Aug, 06, 2026

50 people who take Leukeran and Thalidomide together, and have interactions are studied.

Leukeran and Thalidomide drug interactions.

What are the common drug interactions of Leukeran and Thalidomide, by gender? *:

female:

Failure to thrive (inadequate weight gain and physical growth in children)
Febrile neutropenia (fever with reduced white blood cells)
Fibrocystic breast disease (a condition causing breast pain, cysts, and noncancerous breast lumps, affects many women)
Foot fracture
Gait disturbance
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Haematuria (presence of blood in urine)
Herpes zoster
Hyperlipidaemia (presence of excess lipids in the blood)
Hypertension (high blood pressure)

male:

Enterococcal infection
Septic shock (shock due to blood infection)
Dysphagia (a condition in which swallowing is difficult or painful)
Tenderness (pain or discomfort when an affected area is touched)
Thrombocytopenia (decrease of platelets in blood)
Malignant neoplasm progression (cancer tumour came back)
Abdominal pain upper
Asthenia (weakness)
General physical condition
Inflammatory marker increased

What are the common drug interactions of Leukeran and Thalidomide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Blood pressure decreased
Infection
General physical health deterioration (weak health status)
Procalcitonin increased
Waldenstrom's macroglobulinaemia (cancer affects small lymphocytes (white blood cells))
Anaemia (lack of blood)
Body temperature increased
Cachexia (loss of weight)
Dysphagia (a condition in which swallowing is difficult or painful)
Tenderness (pain or discomfort when an affected area is touched)

60+:

Anaemia (lack of blood)
Bone disorder
Contusion (a type of hematoma of tissue in which capillaries)
Disability
Dizziness
Ear infection
Excoriation (to tear or wear off the skin of)
Hyperglycaemia (high blood sugar)
Hypoglycaemia (deficiency of glucose in the bloodstream)
Injury

What are the existing conditions these people have? *

Waldenstrom's Macroglobulinaemia (cancer affects small lymphocytes (white blood cells)): 36 people, 72.00%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 21 people, 42.00%
Multiple Myeloma (cancer of the plasma cells): 4 people, 8.00%
Immunodeficiency Disorders: 4 people, 8.00%
Disease Progression: 4 people, 8.00%
Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 4 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Leukeran and Thalidomide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously